Opioid Use Disorders

Child and Adolescent Psychiatric Clinics of North America

Volumn 25, Issue 3, 2016, Pages 473-487

  Sharma, Bikash ^a   Bruner, Ann ^a,b   Barnett, Gabrielle ^a   Fishman, Marc ^a,b  

^a Mountain Manor Treatment Center   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heroin; Injection; Opioid use disorder; Opioids; Overdose; Prescription opioids; Withdrawal

Indexed keywords

BUPRENORPHINE; CLONIDINE; DRUGS USED IN THE TREATMENT OF ADDICTION; ILLICIT DRUG; NALOXONE; NALTREXONE; OPIATE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADOLESCENT DISEASE; AGE; ASSISTED VENTILATION; CLINICAL FEATURE; COMORBIDITY; CONSENSUS; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DETOXIFICATION; DRUG MISUSE; DRUG OVERDOSE; EMERGENCY TREATMENT; EPIDEMIC; EVIDENCE BASED MEDICINE; FAMILY ATTITUDE; FAMILY THERAPY; GENDER; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; MORTALITY; NONHUMAN; OPIATE ADDICTION; PATIENT ASSESSMENT; PATIENT COUNSELING; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOSOCIAL DISORDER; RACE; RELAPSE; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; SYMPTOM; VIRUS TRANSMISSION; WITHDRAWAL SYNDROME; ADOLESCENT; OPIOID-RELATED DISORDERS;

ADOLESCENT; ANALGESICS, OPIOID; BUPRENORPHINE; DRUG OVERDOSE; HUMANS; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 84963516846     PISSN: 10564993     EISSN: 15580490     Source Type: Journal    
DOI: 10.1016/j.chc.2016.03.002     Document Type: Review

References (64)

1. Muhuri P.K., Gfroerer J.C., Davies C. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the US. Center for Behavioral Health Statistics and Quality Data Review. 2013, SAMHSA, Available at: http://archive.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.htm. Accessed October 12, 2015.
2. Subramaniam G.A., Stitzer M.A. Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder. Drug Alcohol Depend 2009, 101:13-19.
3. Subramaniam G.A., Stitzer M.A., Woody G., et al. Clinical characteristics of treatment seeking adolescents with opioid versus cannabis/alcohol use disorders. Drug Alcohol Depend 2009, 99(1-3):141-149.
4. Mills K.L., Teesson M., Darke S., et al. Young people with heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat 2004, 27:67-73.
5. Uhl G.R., Grow R.W. The burden of complex genetics in brain disorders. Arch Gen Psychiatry 2004, 61(3):223-229.
6. Merikangas K.R., Stolar M., Stevens D.E., et al. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998, 55(11):973-979.
7. Tsuang M.T., Lyons M.J., Meyer J.M., et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998, 55(11):967-997.
8. Kendler K.S., Jacobson K.C., Prescott C.A., et al. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 2003, 160(4):687-695.
9. Nelson E.C., Agrawal A., Heath A.C., et al. Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry 2015, [Epub ahead of print].
10. Kreek M.J., Levran O., Reed B., et al. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest 2012, 122(10):3387-3393.
11. Volkow N.D., Frieden T.R., Hyde P.S., et al. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med 2014, 370(22):2063-2066.
12. Fortuna R.J., Robbins B.W., Caiola E., et al. Prescribing of controlled medications to adolescents and young adults in the United States. Pediatrics 2010, 126:1108-1116.
13. Anderson P., Chisholm D., Fuhr D.C. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet 2009, 373:2234-2246.
14. Chaloupka F., Straif K., Leon M.E., et al. Effectiveness of tax and price policies in tobacco control. Tob Control 2011, 20:235-238.
15. Kuehn B.M. Medication helps make therapy work for teens addicted to prescription opioids. JAMA 2010, 303:2343-2345.
16. Gordon S.M., Mulvaney F., Rowan A. Characteristics of adolescents in residential treatment for heroin dependence. Am J Drug Alcohol Abuse 2004, 30:593-603.
17. Werb D., Kerr T., Nosyk B., et al. BMJ Open. The temporal relationship between drug supply indicators: an audit of international government surveillance systems. BMJ Open 2013, 3(9):e003077.
18. Hopfer C.J., Khuri E., Crowley T.J., et al. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat 2002, 23:231-237.
19. National Institute on Drug Abuse. Prescription Opioid and Heroin Abuse. Presented by Nora D. Volkow, M.D.House Committee on Energy and Commerce Subcommittee on Oversight and Investigations. Available at:. Accessed April 29, 2014. http://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2015/prescription-opioid-heroin-abuse.
20. Johnston L.D., O'Malley P.M., Bachman J.G., et al. Monitoring the future National Survey Results On Drug Use, 1975-2010. vol. 1: Secondary school students 2011, Institute for Social Research, The University of Michigan, Ann Arbor (MI).
21. Substance Abuse and Mental Health Services Administration Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48 2014, HHS Publication No. (SMA) 14-4863, Substance Abuse and Mental Health Services Administration, Rockville (MD), Available at:. http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.htm.
22. McCabe S.E., West B.T., Boyd C.J. Motives for medical misuse of prescription opioids among adolescents. J Pain 2013, 14(10):1208-1216.
23. McCabe S.E., West B.T., Teter C.J., et al. Medical and nonmedical use of prescription opioids among high school seniors in the United States. Arch Pediatr Adolesc Med 2012, 166(9):797-802.
24. Substance Abuse and Mental Health Services Administration; The NSDUH report, State Estimates of Nonmedical Use of Prescription Pain Relievers. Available at:. Accessed January 8, 2013. http://archive.samhsa.gov/data/2k12/NSDUH115/sr115-nonmedical-use-pain-relievers.htm.
25. Substance Abuse and Mental Health Services Administration Results from the 2006 national survey on drug use and health: national findings 2007, SAMHSA, Rockville (MD), Available at:. http://files.eric.ed.gov/fulltext/ED498206.pdf.
26. Substance Abuse and Mental Health Services Administration; Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2013 and 2014. Table 1.18A - Nonmedical Use of Pain Relievers in Lifetime, Past Year, and Past Month, by Detailed Age Category: Numbers in Thousands, 2013 and 2014. Available at:. Accessed October 9, 2015. http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.htm#tab1-18b.
27. Branson C.E., Clemmey P., Harrell P., et al. Polysubstance use and heroin relapse among adolescents following residential treatment. J Child Adolesc Subst Abuse 2012, 21:204-221.
28. Chen C.Y., Storr C.L., Anthony J.C. Early-onset drug use and risk for drug dependence problems. Addict Behav 2009, 34(3):319-322.
29. Windle M., Windle R.C. Early onset problem behaviors and alcohol, tobacco, and other substance use disorders in young adulthood. Drug Alcohol Depend 2012, 121(1-2):152-158.
30. Subramaniam G.A., Ives M.L., Stitzer M.A., et al. The added risk of opioid problem use among treatment-seeking youth with marijuana and/or alcohol problem use. Addiction 2010, 105:686-698.
31. Barry D., Syed H., Smyth B.P. The journey into injecting heroin use. HARCP 2012, 14(3):89-100.
32. Chiang S., Chen S., Sun H., et al. Heroin use among youths incarcerated for illicit drug use: psychosocial environment, substance use history, psychiatric comorbidity, and route of administration. Am J Addict 2006, 15:233-241.
33. Hopfer C.J., Mikulich S.K., Crowley T.J. Heroin use among adolescents in treatment for substance use disorders. J Am Acad Child Adolesc Psychiatry 2000, 39:1316-1323.
34. Fuller C.M., Vlahov D., Ompad D.C., et al. High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: a case-control study. Drug Alcohol Depend 2002, 66:189-198.
35. Clemmey P., Payne L., Fishman M. Clinical characteristics and treatment outcomes of adolescent heroin users. J Psychoactive Drugs 2004, 36:85-94.
36. Woodcock E.A., Lundahl L.H., Stoltman J.J., et al. Progression to regular heroin use: examination of patterns, predictors, and consequences. Addict Behav 2015, 45:287-293.
37. Goldsamt L.A., Harocopos A., Kobrak P., et al. Circumstances, pedagogy and rationales for injection initiation among new drug injectors. J Community Health 2010, 35(3):258-267.
38. Pugatch D., Strong L.L., Has P., et al. Heroin use in adolescents and young adults admitted for drug detoxification. J Subst Abuse 2001, 13:337-346.
39. Eaves C.S. Heroin use among female adolescents: the role of partner influence in path of initiation and route of administration. Am J Drug Alcohol Abuse 2004, 30:21-38.
40. Doherty M.C., Garfein R.S., Monterroso E., et al. Gender differences in the initiation of injection drug use among young adults. J Urban Health 2000, 77:396-414.
41. Canfield M.C., Keller C.E., Frydrych L.M., et al. Prescription opioid use among patients seeking treatment for opioid dependence. J Addict Med 2010, 4:108-113.
42. Gandhi D.H., Kavanagh G.J., Jaffe J.H. Young heroin users in Baltimore: a qualitative study. Am J Drug Alcohol Abuse 2006, 32:177-188.
43. Substance Abuse and Mental Health Services Administration Treatment Episode Data Set (TEDS). 1999-2009. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-56 2011, HHS Publication No. (SMA) 11-4646, Substance Abuse and Mental Health Services Administration, Rockville (MD), Available at:. http://wwwdasis.samhsa.gov/teds09/TEDS2k9NWeb.pdf.
44. Neaigus A., Miller M., Friedman S.R., et al. Potential risk factors for the transition to injecting among non-injecting heroin users: a comparison of former injectors and never injectors. Addiction 2001, 96(6):847-860.
45. Neaigus A., Gyarmathy V.A., Miller M., et al. Transitions to injecting drug use among noninjecting heroin users: social network influence and individual susceptibility. J Acquir Immune Defic Syndr 2006, 41(4):493-503.
46. Hadland S.E., Werb D., Kerr T., et al. Childhood sexual abuse and risk for initiating injection drug use: a prospective cohort study. Prev Med 2012, 55(5):500-504.
47. Ompad D.C., Ikeda R.M., Shah N., et al. Childhood sexual abuse and age at initiation of injection drug use. Am J Public Health 2005, 95(4):703-709.
48. National Institute on Drug Abuse. Overdose Death Rates. Available at:. Accessed September 21, 2015. http://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates.
49. Centers for Disease Control and Prevention Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011, 60:1487-1492. Available at:. http://www.cdc.gov/vitalsigns/PainkillerOverdoses/index.html.
50. Rudd R.A., Paulozzi L.J., Bauer M.J., Centers for Disease Control and Prevention, et al. Increases in heroin overdose deaths 28 States, 2010 to 2012. MMWR Morb Mortal Wkly Rep 2014, 63(39):849-854. Atlanta, GA: Centers for Disease Control and Prevention.
51. Chen L.H., Hedegaard H., Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief 2014, (166):1-8.
52. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network report: trends in emergency visits involving nonmedical use of narcotic pain relievers, 2010. Available at:. Accessed October 9, 2015. http://www.samhsa.gov/data/sites/default/files/DAWN096/DAWN096/SR096EDHighlights2010.htm.
53. Substance Abuse and Mental Health Services Administration Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits 2013, HHS Publication No. (SMA) 13-4760, DAWN Series D-39, Substance Abuse and Mental Health Services Administration, Rockville (MD), Available at:. http://www.samhsa.gov/data/sites/default/files/DAWN2k11ED/DAWN2k11ED/DAWN2k11ED.pdf.
54. Subramaniam G.A., Fishman M.J., Woody G. Treatment of opioid-dependent adolescents and young adults with buprenorphine. Curr Psychiatry Rep 2009, 11(5):360-363.
55. Fishman M.J., Winstanley E.L., Curran E., et al. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction 2010, 105:1669-1676.
56. Wu L., Woody G.E., Yang C., et al. How do prescription opioid users differ from users of heroin or other drugs in psychopathology? Results from the National Epidemiological Survey on Alcohol and Related Conditions. J Addict Med 2011, 5:28-35.
57. Riggs P.D., Mikulich S.K., Davies R.D., et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med 2007, 161:1026-1034.
58. Wesson D.R., Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003, 35(2):253-259. Available at:. https://www.drugabuse.gov/sites/default/files/files/ClinicalOpiateWithdrawalScale.pdf.
59. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 1998-2008. State Admissions to Substance Abuse Treatment Services, DASIS Series: S-55, HHS Publication No. (SMA) 10-4613. Rockville (MD): 2010. Available at:. Accessed October 12, 2015. http://wwwdasis.samhsa.gov/teds08/TEDS2k8Sweb.pdf.
60. Warden D., Subramaniam G.A., Carmody T., et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict Behav 2012, 37(9):1046-1053.
61. Woody G.E., Poole S.A., Subramaniam G., et al. Extended vs short term buprenorphine- naloxone for treatment of opioid- addicted youth: a randomized trial. JAMA 2008, 300:2003-2020.
62. Krupitsky E., Nunes E.V., Ling W., et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011, 377(9776):1506-1513.
63. Schuman-Olivier Z., Weiss R.D., Hoeppner B.B., et al. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat 2014, 47(3):202-212.
64. Dreifuss J.A., Griffin M.L., Frost K., et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: results from a multisite study. Drug Alcohol Depend 2013, 131(1-2):112-118.